Int J Stomatol ›› 2021, Vol. 48 ›› Issue (6): 731-736.doi: 10.7518/gjkq.2021094
• Reviews • Previous Articles Next Articles
CLC Number:
[1] |
Seethala RR, Stenman G. Update from the 4th edition of the world health organization classification of head and neck tumours: tumors of the salivary gland[J]. Head Neck Pathol, 2017, 11(1):55-67.
doi: 10.1007/s12105-017-0795-0 pmid: 28247227 |
[2] |
Jayaprakash V, Merzianu M, Warren GW, et al. Survival rates and prognostic factors for infiltrating salivary duct carcinoma: analysis of 228 cases from the surveillance, epidemiology, and end results database[J]. Head Neck, 2014, 36(5):694-701.
doi: 10.1002/hed.v36.5 |
[3] |
Osborn V, Givi B, Lee A, et al. Characterization, treatment and outcomes of salivary ductal carcinoma using the National Cancer Database[J]. Oral Oncol, 2017, 71:41-46.
doi: 10.1016/j.oraloncology.2017.05.005 |
[4] |
Dalin MG, Desrichard A, Katabi N, et al. Comprehensive molecular characterization of salivary duct carcinoma reveals actionable targets and similarity to apocrine breast cancer[J]. Clin Cancer Res, 2016, 22(18):4623-4633.
doi: 10.1158/1078-0432.CCR-16-0637 |
[5] | 何时, 何同梅, 卢建平, 等. 31例涎腺导管癌的临床病理分析[J]. 临床与病理杂志, 2019, 39(7):41-49. |
He S, He TM, Lu JP, et al. Clinicopathologic fea-tures of 31 cases of salivary duct carcinoma[J]. Int J Path Clin Med, 2019, 39(7):41-49. | |
[6] |
Kleinsasser O, Klein HJ, Hübner G. Salivary duct carcinoma. A group of salivary gland tumors analogous to mammary duct carcinoma[J]. Arch Klin Exp Ohren Nasen Kehlkopfheilkd, 1968, 192(1):100-105.
pmid: 4301301 |
[7] |
Luk PP, Weston JD, Yu B, et al. Salivary duct carcinoma: clinicopathologic features, morphologic spectrum, and somatic mutations[J]. Head Neck, 2016, 38(Suppl 1):E1838-E1847.
doi: 10.1002/hed.24332 |
[8] |
Enomoto T, Aoki M, Miyagawa K, et al. A case of salivary duct carcinoma intracranial invasion due to perineural invasion through the facial nerve[J]. World Neurosurg, 2020, 140:332-337.
doi: 10.1016/j.wneu.2020.05.180 |
[9] |
Wu WL, Wang CL, Li D, et al. Multiphase contrast-enhanced computed tomography imaging features of salivary duct carcinoma: differentiation from other salivary gland malignancies[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2019, 128(5):543-551.
doi: 10.1016/j.oooo.2019.05.011 |
[10] | 李子园, 管民, 窦社伟, 等. 涎腺导管癌CT及MRI影像特征分析[J]. 中华实用诊断与治疗杂志, 2021, 35(2):181-184. |
Li ZY, Guan M, Dou SW, et al. CT and MRI features of salivary duct carcinoma[J]. J Chin Pract Diagn Ther, 2021, 35(2):181-184. | |
[11] |
Nakaguro M, Sato Y, Tada Y, et al. Prognostic implication of histopathologic indicators in salivary duct carcinoma: proposal of a novel histologic risk stratification model[J]. Am J Surg Pathol, 2020, 44(4):526-535.
doi: 10.1097/PAS.0000000000001413 pmid: 31764219 |
[12] |
Pfister DG, Spencer S, Adelstein D, et al. Head and neck cancers, version 2.2020, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2020, 18(7):873-898.
doi: 10.6004/jnccn.2020.0031 |
[13] |
Alame M, Cornillot E, Cacheux V, et al. The mole-cular landscape and microenvironment of salivary duct carcinoma reveal new therapeutic opportunities[J]. Theranostics, 2020, 10(10):4383-4394.
doi: 10.7150/thno.42986 |
[14] |
Gargano SM, Senarathne W, Feldman R, et al. No-vel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling[J]. Cancer Med, 2019, 8(17):7322-7329.
doi: 10.1002/cam4.v8.17 |
[15] |
Wang K, Russell JS, McDermott JD , et al. Profiling of 149 salivary duct carcinomas, carcinoma ex pleomorphic adenomas, and adenocarcinomas, not otherwise specified reveals actionable genomic alterations[J]. Clin Cancer Res, 2016, 22(24):6061-6068.
pmid: 27334835 |
[16] | Aoki M, Fujishita T. Oncogenic roles of the PI3K/AKT/mTOR axis[J]. Curr Top Microbiol Immunol, 2017, 407:153-189. |
[17] |
Takács T, Kudlik G, Kurilla A, et al. The effects of mutant Ras proteins on the cell signalome[J]. Cancer Metastasis Rev, 2020, 39(4):1051-1065.
doi: 10.1007/s10555-020-09912-8 |
[18] |
Xu F, Na LX, Li YF, et al. Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative di-seases and tumours[J]. Cell Biosci, 2020, 10:54.
doi: 10.1186/s13578-020-00416-0 |
[19] |
Ettl T, Schwarz-Furlan S, Haubner F, et al. The PI3K/AKT/mTOR signalling pathway is active in salivary gland cancer and implies different functions and pro-gnoses depending on cell localisation[J]. Oral Oncol, 2012, 48(9):822-830.
doi: 10.1016/j.oraloncology.2012.02.021 |
[20] | Tewari D, Patni P, Bishayee A, et al. Natural pro-ducts targeting the PI3K-Akt-mTOR signaling pathway in cancer: a novel therapeutic strategy[J]. Se-min Cancer Biol, 2019: S1044- S579X(19)30405-5. |
[21] |
Suzuki S, Dobashi Y, Minato H, et al. EGFR and HER2-Akt-mTOR signaling pathways are activated in subgroups of salivary gland carcinomas[J]. Virchows Arch, 2012, 461(3):271-282.
doi: 10.1007/s00428-012-1282-3 |
[22] |
Oh DY, Bang YJ. HER2-targeted therapies-a role beyond breast cancer[J]. Nat Rev Clin Oncol, 2020, 17(1):33-48.
doi: 10.1038/s41571-019-0268-3 |
[23] |
Santana T, Pavel A, Martinek P, et al. Biomarker immunoprofile and molecular characteristics in saliva-ry duct carcinoma: clinicopathological and prognostic implications[J]. Hum Pathol, 2019, 93:37-47.
doi: 10.1016/j.humpath.2019.08.009 |
[24] |
Williams MD, Roberts DB, Kies MS, et al. Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance[J]. Clin Cancer Res, 2010, 16(8):2266-2274.
doi: 10.1158/1078-0432.CCR-09-0238 |
[25] |
Valabrega G, Montemurro F, Aglietta M. Trastuzu-mab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer[J]. Ann Oncol, 2007, 18(6):977-984.
pmid: 17229773 |
[26] |
Hanna GJ, Bae JE, Lorch JH, et al. The benefits of adjuvant trastuzumab for HER-2-positive salivary gland cancers[J]. Oncologist, 2020, 25(7):598-608.
doi: 10.1634/theoncologist.2019-0841 |
[27] |
Takahashi H, Tada Y, Saotome T, et al. PhaseⅡtrial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive sa-livary duct carcinoma[J]. J Clin Oncol, 2019, 37(2):125-134.
doi: 10.1200/JCO.18.00545 pmid: 30452336 |
[28] |
Limaye SA, Posner MR, Krane JF, et al. Trastuzu-mab for the treatment of salivary duct carcinoma[J]. Oncologist, 2013, 18(3):294-300.
doi: 10.1634/theoncologist.2012-0369 |
[29] |
Arafeh R, Samuels Y. PIK3CA in cancer: the past 30 years[J]. Semin Cancer Biol, 2019, 59:36-49.
doi: S1044-579X(18)30152-4 pmid: 30742905 |
[30] | Qiu WL, Tong GX, Turk AT, et al. Oncogenic PIK-3CA mutation and dysregulation in human salivary duct carcinoma[J]. Biomed Res Int, 2014, 2014:81-0487. |
[31] |
Griffith CC, Seethala RR, Luvison A, et al. PIK3CA mutations and PTEN loss in salivary duct carcinomas[J]. Am J Surg Pathol, 2013, 37(8):1201-1207.
doi: 10.1097/PAS.0b013e3182880d5a |
[32] |
Nardi V, Sadow PM, Juric D, et al. Detection of no-vel actionable genetic changes in salivary duct carcinoma helps direct patient treatment[J]. Clin Cancer Res, 2013, 19(2):480-490.
doi: 10.1158/1078-0432.CCR-12-1842 |
[33] |
Juric D, Rodon J, Tabernero J, et al. Phosphatidy-linositol 3-kinase α-selective inhibition with alpeli-sib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study[J]. J Clin Oncol, 2018, 36(13):1291-1299.
doi: 10.1200/JCO.2017.72.7107 |
[34] |
Saintigny P, Mitani Y, Pytynia KB, et al. Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: implications for targeted therapy[J]. Cancer, 2018, 124(18):3693-3705.
doi: 10.1002/cncr.31600 pmid: 30289966 |
[35] |
Arolt C, Meyer M, Ruesseler V, et al. Lymphocyte activation gene 3 (LAG3) protein expression on tumor-infiltrating lymphocytes in aggressive and TP53-mutated salivary gland carcinomas[J]. Cancer Immunol Immunother, 2020, 69(7):1363-1373.
doi: 10.1007/s00262-020-02551-6 |
[36] |
Luk PP, Weston JD, Yu B, et al. Salivary duct carcinoma: clinicopathologic features, morphologic spectrum, and somatic mutations[J]. Head Neck, 2016, 38(Suppl 1):E1838-E1847.
doi: 10.1002/hed.24332 |
[37] |
Fu Y, Cruz-Monserrate Z, Helen Lin H, et al. Ductal activation of oncogenic KRAS alone induces sarcomatoid phenotype[J]. Sci Rep, 2015, 5:13347.
doi: 10.1038/srep13347 |
[38] |
Athuluri-Divakar SK, Vasquez-Del Carpio R, Dutta K , et al. A small molecule RAS-mimetic disrupts RAS association with effector proteins to block signaling[J]. Cell, 2016, 165(3):643-655.
doi: 10.1016/j.cell.2016.03.045 pmid: 27104980 |
[39] |
Spencer-Smith R, Koide A, Zhou Y, et al. Inhibition of RAS function through targeting an allosteric regulatory site[J]. Nat Chem Biol, 2017, 13(1):62-68.
doi: 10.1038/nchembio.2231 pmid: 27820802 |
[40] | Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use[J]. Cold Spring Harb Perspect Biol, 2010, 2(1):a001008. |
[41] |
Abraham AG, O’Neill E . PI3K/Akt-mediated regulation of p53 in cancer[J]. Biochem Soc Trans, 2014, 42(4):798-803.
doi: 10.1042/BST20140070 |
[42] |
Carracedo A, Alimonti A, Pandolfi PP. PTEN level in tumor suppression: how much is too little[J]. Cancer Res, 2011, 71(3):629-633.
doi: 10.1158/0008-5472.CAN-10-2488 pmid: 21266353 |
[43] |
Gharbi SI, Zvelebil MJ, Shuttleworth SJ, et al. Exploring the specificity of the PI3K family inhibitor LY294002[J]. Biochem J, 2007, 404(1):15-21.
doi: 10.1042/BJ20061489 |
[44] |
Ettl T, Baader K, Stiegler C, et al. Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer[J]. Br J Cancer, 2012, 106(4):719-726.
doi: 10.1038/bjc.2011.605 |
[1] | Han Chong,He Dongning,Yu Feiyan,Wu Dongchao. Research progress on the mechanism and treatment of pain after oral implants [J]. Int J Stomatol, 2024, 51(1): 99-106. |
[2] | Li Tan,Liang Xin-hua.. Role of discoidin domain receptor 1 in the regulation of malignant tumor progression and therapy [J]. Int J Stomatol, 2023, 50(2): 230-236. |
[3] | Jiang Yulei,Xia Bin,Rao Nanquan,Yang Hefeng,Xu Biao. Exosomes mediate the malignant progression of oral squamous cell carcinoma and its application in diagnosis and treatment [J]. Int J Stomatol, 2021, 48(6): 711-717. |
[4] | Qian Ying,Gong Jiaxing,Yu Mengfei,Liu Yu,Wei Dong,Zhu Ziyu,Lu Kejie,Wang Huiming. Diagnosis and treatment of ameloblastoma from molecular biology perspective [J]. Int J Stomatol, 2021, 48(5): 570-578. |
[5] | Ma Pingchuan,Li Chunjie,Li Longjiang. Diagnosis and treatment of salivary duct carcinoma [J]. Int J Stomatol, 2021, 48(4): 459-467. |
[6] | Zhu Junjin,Zhou Jiaqi,Wu Yingying. Function of autophagy induced by mammalian target of rapamycin complex 1 in bone metabolism [J]. Int J Stomatol, 2020, 47(1): 84-89. |
[7] | Dingli Feng,Lidan Zhuo,Di Lu,Hongyan Guo. Mechanism of microRNA modulation of cartilage differentiation in mesenchymal stem cells [J]. Inter J Stomatol, 2018, 45(6): 640-645. |
[8] | Chuan Fang,Yadong Li. Investigative progresses of microRNA in oral squamous cell carcinoma [J]. Inter J Stomatol, 2018, 45(6): 646-651. |
[9] | Wang Liping, Zha Jun, Ge Linhu.. Research progress on non-coding RNAs in tongue squamous cell carcinoma [J]. Inter J Stomatol, 2018, 45(4): 420-424. |
[10] | Xiao Yandi, Yang Huamei, Dan Hongxia. Adverse reactions of targeted anticancer agents in oral cavity: manifestation and management [J]. Inter J Stomatol, 2018, 45(2): 140-144. |
[11] | Zhou Ying, Jiang Yihua. Gene expression analysis of oral squamous cell carcinoma and adjacent tissues [J]. Inter J Stomatol, 2015, 42(3): 310-313. |
[12] | Xu Yuanming, Fan Mingwen, Yang Xuechao. Application of mesenchymal stem cell in tumor targeted therapy [J]. Inter J Stomatol, 2013, 40(3): 371-374. |
[13] |
Wang Lin 1,Pu Yinfei 1,Wang Yixiang 2,Guo Chuanbin 1 . .
The application prospects of probiotic Bifidobacterium in the tumor targeted therapy
[J]. Inter J Stomatol, 2013, 40(2): 268-272.
|
[14] | Li Ling, Shi Bing.. MicroRNA-140 and its function in craniofacial development [J]. Inter J Stomatol, 2011, 38(4): 419-422. |
[15] | LIU Xiang-jie, HU Ji-an.. Research progress on treatment of Sjögren′s syndrome [J]. Inter J Stomatol, 2010, 37(5): 589-592. |